Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Hello Cancer Coach- I watched your webinar about multiple myeloma (MM) last week because I’m trying to find some answers that my doctor can’t give me.
Now the doctor wants to put me on Revlimid for the rest of my life!!! You don’t know me, but I’m 47…make that 48 (it’s my birthday today 😊)
I’m in shape, I bike or run about 5-6 times a week. I can say that in a pretty good shape!! I didn’t stop training while I was on chemo. I eat nutritiously as I have been a vegetarian since about 5 years now. I think I have a healthy life! When I found out I had MM I did reduce sugar from my meals… This is difficult as I like desert!
I really like your story that I just read on the Burzynski Patient Website. It seems like you don’t take toxic chemotherapy and haven’t for a longtime now. Is it the case? I just want to know if there’s a chance to get a good life without chemotherapy…
I don’t like the side effects of chemotherapy. I believe that we can fight MM with non-toxic therapies.
Also, Antineoplaton Therapy (ANP) is not available here in Canada. Are you still taking ANP?
Hope to hear from you soon-
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
“In CALGB 100104, among 231 patients randomized to receive lenalidomide vs 229 randomized to receive placebo, median progression-free survival was 33.9 vs 19.0 months… In IFM 2005-02, among 307 lenalidomide patients vs 307 placebo patients, median progression-free survival was 41.2 vs 23.0 months… At updated overall survival analysis in February 2016, median overall survival was 111.0 vs 84.2 months in CALGB 100104 and 105.9 vs 88.1 months in IFM 2005-02.
How It Works- Lenalidomide is a thalidomide (Thalomid) analog with immunomodulatory, antiangiogenic, and antineoplastic properties. It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells, including mantle cell lymphoma, multiple myeloma, and del(5q) myelodysplastic syndrome in vitro and delays tumor growth in hematopoietic tumor models including multiple myeloma…
The combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis in multiple myeloma cells…
The most common adverse events of any grade across both maintenance studies (> 20% of lenalidomide patients) were neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, nasopharyngitis, cough, gastroenteritis, diarrhea, rash, fatigue, asthenia, muscle spasm, and pyrexia. The most common grade 3 or 4 adverse events in the two studies (vs placebo) included neutropenia (59% vs 33% and 54% vs 8%), thrombocytopenia (38% vs 30% and 13% vs 3%), and leukopenia (20% vs 10% and 24% vs 2%).
Serious adverse events occurring in > 4.5% of lenalidomide patients were lung infection and neutropenia. The most common adverse events leading to discontinuation of lenalidomide were thrombocytopenia (2.7%) and neutropenia (2.4%).
In patients receiving lenalidomide maintenance therapy following high-dose intravenous melphalan and autologous stem cell transplant, hematologic second primary malignancies occurred in 7.5% of patients compared to 3.3% of patients receiving placebo…”